Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.35 |
| ▸ | GHSR | Q92847 | 6/20 | 0.35 |
| ▸ | BRAF | P15056 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5776661 | 0.90 | PTGS2 (0.45) | PTGS2GHSRMAPTHTTSMN1; SMN2 | |
| SCHEMBL5776886 | 0.77 | PTGS2 (0.49) | PTGS2GPBAR1GHSRBRAFHTT | |
| SCHEMBL6692596 | 0.77 | BRAF (0.40) | BRAFMAPTHTTSMN1; SMN2POLB | |
| SCHEMBL5778310 | 0.75 | POLB (0.51) | PTGS2GPBAR1GHSRBRAFMAPT | |
| SCHEMBL6692603 | 0.75 | BRAF (0.38) | BRAFMAPTGAAPOLBMEN1 | |
| SCHEMBL5774936 | 0.74 | PTGS2 (0.42) | PTGS2GPBAR1GHSRBRAFMAPT | |
| SCHEMBL5777332 | 0.74 | PTGS2 (0.42) | PTGS2GPBAR1GHSRBRAFMAPT | |
| SCHEMBL5774719 | 0.74 | PTGS2 (0.48) | PTGS2GHSRMAPTHTTSMN1; SMN2 | |
| SCHEMBL7226348 | 0.74 | PTGS2 (0.45) | PTGS2GPBAR1GHSRBRAFHTT | |
| SCHEMBL6691783 | 0.71 | PTGS2 (0.39) | PTGS2GPBAR1BRAFMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077675-A1 | Compounds and methods for inhibiting MRP1 | BONJOUKLIAN ROSANNE (US) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077675-A1 | Compounds and methods for inhibiting MRP1 | ABCC1, ABCB1, ABCB11 | PTGS2 1354/4885GPBAR1 176/4885GHSR 4725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.